First clinical AI technology company to join London Stock Exchange
LONDON, UK; 20 August 2018 – Consilium Strategic Communications, a global leader in strategic healthcare communications, announces that it advised Sensyne Health plc, a British clinical AI technology company, on PR and IR activities surrounding its successful Initial Public Offering (“IPO”) on London Stock Exchange’s AIM raising £60 million. Sensyne commenced trading under the ticker “SENS.L.” on Friday 17 August 2018 with a market capitalisation of £225 million.
Sensyne Health is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis and commercialisation of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trust partners. Sensyne Health has already signed partnerships with three NHS Trusts including Oxford University Hospitals, South Warwickshire and Chelsea and Westminster NHS Foundation Trusts.
Sensyne Health, in collaboration with its NHS partners, uses proprietary clinical artificial intelligence algorithms developed by researchers at the University of Oxford and Oxford University Hospitals NHS Foundation Trust to discover new insights that improve patient care and are of significant value to pharmaceutical companies throughout the research, development and commercialisation process for medicines.
The funds raised from the IPO will primarily be used to expand Sensyne’s team in order to deliver on the business strategy.
Peel Hunt LLP acted as Bookrunner in connection with the Placing and is Nominated Adviser and Broker to Sensyne Health.
“We are delighted to have advised Sensyne Health, a leading healthtech company focused on clinical AI, on its financial and strategic communications during the successful IPO and look forward to supporting the business as it now commences PLC life on the London Stock Exchange. Sensyne is the first clinical AI technology company to join the London Stock Exchange and the work exemplifies Consilium’s position as a leader in advising innovative healthtech companies as we contine to operate in a big data era.”
Mary-Jane Elliott
Managing Partner, Consilium Strategic Communications
“Consilium have done an outstanding job as communication advisors to Sensyne Health and have proven to be the right team to work with throughout our IPO process. Proactive, professional and thoughtful with the contacts and the experience to guide us through and the know-how and energy to help deliver a successful result. They are a pleasure to work with and we are looking forward to a long term relationship during our new life as a public company.”
Lord (Paul) Drayson
